{"id":508758,"date":"2021-07-01T08:03:45","date_gmt":"2021-07-01T12:03:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/"},"modified":"2021-07-01T08:03:45","modified_gmt":"2021-07-01T12:03:45","slug":"entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/","title":{"rendered":"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens"},"content":{"rendered":"
\n

WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics<\/a> Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.<\/p>\n

At the World Microbe Forum, Entasis scientists presented their approach to the discovery of ETX0462 that incorporated Structure-Porin Permeation Relationships and Structure-Based Drug Design to identify key principles for penicillin-binding protein (PBP) inhibition and corresponding antimicrobial activity against contemporary MDR Gram-negative and biothreat isolates, including P. aeruginosa, K. pneumoniae, S. maltophilia, E. coli, B. anthracis, Y. pestis, F. tularensis and Burkholderia <\/em>spp. <\/em>Entasis scientists further demonstrated that the activity of ETX0462 was unaffected by all four Ambler classes of \u03b2-lactamases and has a low propensity for resistance emergence due to its ability to permeate bacterial cells through multiple porins and inhibit several PBPs.<\/p>\n

\u201cETX0462 is the latest product candidate to emerge from our discovery platform and the first example of a novel class of agents targeting the established mechanism of \u03b2-lactam antibiotics without being susceptible to the most common \u03b2-lactam resistance mechanism, \u03b2-lactamases,\u201d commented Ruben Tommasi, Chief Scientific Officer at Entasis. \u201cWe look forward to continuing our successful collaboration with CARB-X as we progress ETX0462 towards the clinic.\u201d<\/p>\n

In in vivo<\/em> studies, ETX0462 exhibited robust bactericidal activity reaching >3-log drop in bacterial count vs. initial inoculum in a neutropenic murine lung model against clinical isolates of P. aeruginosa<\/em>. Similar in vivo<\/em> efficacy was also demonstrated for the biothreat pathogens Y. pestis<\/em> and B. pseudomallei<\/em>. Entasis also shared that the PK\/PD index of ETX0462 is driven by % Time > MIC and a ~60% target for 1-log bactericidal activity. Entasis demonstrated that ETX0462 was well tolerated in a rat 14-day GLP toxicology study reaching the limit dose of 2,000 mg\/kg.<\/p>\n

Additional details of the ETX0462 data presented can be found on the Entasis Presentations<\/a> webpage.<\/p>\n

\n About Entasis Therapeutics Inc.<\/strong>
\n
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii<\/em> infections), zoliflodacin (targeting Neisseria gonorrhoeae<\/em> infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Pseudomonas<\/em> infections). For more information, visit www.entasistx.com<\/a>.<\/p>\n

\n About ETX0462<\/strong>
\n
ETX0462 is a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens including, P. aeruginosa, K. pneumoniae, S. maltophilia, E. coli, B. anthracis, Y. pestis, F. tularensis and Burkholderia spp<\/em>. Similar to \u03b2-lactam antibiotics, ETX0462 inhibits penicillin-binding proteins which are essential for bacterial cell wall biosynthesis, however, unlike \u03b2-lactam antibiotics, ETX0462 is unaffected by \u03b2-lactamase mediated resistance. ETX0462 is supported by CARB-X.<\/p>\n\n\n\n\n\n\n
\n Company Contact<\/strong>\n <\/td>\n\n Investor Contact<\/strong>\n <\/td>\n<\/tr>\n
Kyle Dow<\/td>\nBruce Mackle<\/td>\n<\/tr>\n
Entasis Therapeutics\u00a0 \u00a0<\/td>\nLifeSci Advisors<\/td>\n<\/tr>\n
(781) 810-0114\u00a0<\/td>\n(929) 469-3859<\/td>\n<\/tr>\n
\n kyle.dow@entasistx.com<\/a>\n <\/td>\n\n bmackle@lifesciadvisors.com<\/a>\n <\/td>\n<\/tr>\n<\/table>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections. At the World Microbe Forum, Entasis scientists presented their approach to the discovery of ETX0462 that incorporated Structure-Porin Permeation Relationships and Structure-Based Drug Design to identify key principles for penicillin-binding protein (PBP) inhibition and corresponding antimicrobial activity against contemporary MDR Gram-negative and biothreat isolates, including … <\/p>\n

Continue reading “Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-508758","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEntasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections. At the World Microbe Forum, Entasis scientists presented their approach to the discovery of ETX0462 that incorporated Structure-Porin Permeation Relationships and Structure-Based Drug Design to identify key principles for penicillin-binding protein (PBP) inhibition and corresponding antimicrobial activity against contemporary MDR Gram-negative and biothreat isolates, including … Continue reading "Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T12:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens\",\"datePublished\":\"2021-07-01T12:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/\"},\"wordCount\":516,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/\",\"name\":\"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=\",\"datePublished\":\"2021-07-01T12:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/","og_locale":"en_US","og_type":"article","og_title":"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens - Market Newsdesk","og_description":"WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections. At the World Microbe Forum, Entasis scientists presented their approach to the discovery of ETX0462 that incorporated Structure-Porin Permeation Relationships and Structure-Based Drug Design to identify key principles for penicillin-binding protein (PBP) inhibition and corresponding antimicrobial activity against contemporary MDR Gram-negative and biothreat isolates, including … Continue reading \"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-01T12:03:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens","datePublished":"2021-07-01T12:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/"},"wordCount":516,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/","name":"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=","datePublished":"2021-07-01T12:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYzOCM0Mjc4MDg4IzIwOTU4NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-introduces-etx0462-a-first-in-class-candidate-targeting-multidrug-resistant-gram-negative-and-biothreat-pathogens\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=508758"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508758\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=508758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=508758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=508758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}